Table of Contents
<< Previous Issue | Apr 2024 (Vol: 2024, Issue: 4) |
- Section: Licensing
-
Novartis Pays Arvinas US$150 M Upfront for Prostate Cancer Protein Degrader
- Section: Mergers & Acquisitions
-
Genmab Acquires ADC Drug Developer ProfoundBio for US$1.8 B
-
Vertex Buys Alpine Immune Sciences and its Kidney Disease Drug for US$4.9 B